Apyx Medical price target lowered to $2.50 from $3 at Lake Street

Lake Street lowered the firm’s price target on Apyx Medical to $2.50 from $3 and keeps a Buy rating on the shares following the company’s Q4 report. While “the storm clouds have yet to clear,” the firm maintains a Buy rating, citing what it views as the company’s “best-in-class products” and “a trough multiple.”